Brind.
  1. AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity.

Gilgamesh Pharmaceuticals acquired Bretisilocin, adding depth to Neuro's drug development pipeline.

1 report, 1 independent Updated Aug 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Gilgamesh Pharmaceuticals acquired Bretisilocin, adding depth to Neuro's drug development pipeline.

Who's involved

What this event is mainly about
Gilgamesh PharmaceuticalsAbbVie

Keep exploring

Part of

AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Assessing AbbVie’s Valuation After $1.2B Bretisilocin Acquisition Announcement Trying to decide whether to hold, sell, or even start a position in AbbVie right now? You are not alone. This stock has